|
1
|
Yoo SS, Do SK, Choi JE, Lee SY, Cha SI,
Kim CH and Park JY: TERT Polymorphism rs2853669 Influences on lung
cancer risk in the korean population. J Korean Med Sci.
30:1423–1428. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Griewank KG, Murali R, Schilling B,
Schimming T, Möller I, Moll I, Schwamborn M, Sucker A, Zimmer L,
Schadendorf D and Hillen U: TERT promoter mutations are frequent in
cutaneous basal cell carcinoma and squamouscell carcinoma. PLoS
One. 8:e803542013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin
L and Garraway LA: Highly recurrent TERT promoter mutations in
human melanoma. Science. 339:957–959. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Horn S, Figl A, Rachakonda PS, Fischer C,
Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, et al:
TERT promoter mutations in familial and sporadic melanoma. Science.
339:959–961. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu X, Bishop J, Shan Y, Pai S, Liu D,
Murugan AK, Sun H, El-Naggar AK and Xing M: Highly prevalent TERT
promoter mutations in aggressive thyroid cancers. Endocr Relat
Cancer. 20:603–610. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda
C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL,
Giovanella BC, et al: TERT promoter mutations occur frequently in
gliomas and a subset of tumors derived from cells with low rates of
self-renewal. Proc Natl Acad Sci USA. 110:pp. 6021–6026. 2013;
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vinagre J, Almeida A, Pópulo H, Batista R,
Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, et al:
Frequency of TERT promoter mutations in human cancers. Nat Commun.
4:21852013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Torre LA, Siegel RL and Jemal A: Lung
Cancer Statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Travis WD, Travis LB and Devesa SS: Lung
cancer. Cancer. 75:191–202. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oser MG, Niederst MJ, Sequist LV and
Engelman JA: Transformation from non-small-cell lung cancer to
small-cell-lung cancer: Molecular drivers and cells of origin.
Lancet Oncol. 16:e165–e172. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gertler R, Rosenberg R, Stricker D,
Friederichs J, Hoos A, Werner M, Ulm K, Holzmann B, Nekarda H and
Siewert JR: Telomere length and human telomerase reverse
transcriptase expression as markers for progression and prognosis
of colorectal carcinoma. J Clin Oncol. 22:1807–1814. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Svenson U, Nordfjäll K, Stegmayr B, Manjer
J, Nilsson P, Tavelin B, Henriksson R, Lenner P and Roos G: Breast
cancer survival is associated with telomere length in peripheral
blood cells. Cancer Res. 68:3618–3623. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu T, Wang N, Cao J, Sofiadis A, Dinets
A, Zedenius J, Larsson C and Xu D: The age- and shorter
telomere-dependent TERT promoter mutation in follicular thyroid
cell-derived carcinomas. Oncogene. 33:4978–4984. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Reck M: Gefitinib in the treatment of
advanced non-small-cell lung cancer. Expert Rev Anticancer Ther.
9:401–412. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li C, Hao L, Li Y, Wang S, Chen H, Zhang
L, Ke B, Yin Y, Suo H, Sun B, et al: Prognostic value analysis of
mutational and clinicopathological factors in non-small cell lung
cancer. PLoS One. 9:e1072762014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ma X, Gong R, Wang R, Pan Y, Cai D, Pan B,
Li Y, Xiang J, Li H, Zhang J, et al: Recurrent TERT promoter
mutations in non-small cell lung cancers. Lung Cancer. 86:369–373.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fernández-Marcelo T, Gómez A, Pascua I, De
Juan C, Head J, Hernando F, Jarabo JR, Calatayud J, Torres-García
AJ and Iniesta P: Telomere length and telomerase activity in
non-small cell lung cancer prognosis: Clinical usefulness of a
specific telomere status. J Exp Clin Cancer Res. 34:782015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun B, Wang Y, Kota K, Shi Y, Motlak S,
Makambi K, Loffredo CA, Shields PG, Yang Q, Harris CC and Zheng YL:
Telomere length variation: A potential new telomere biomarker for
lung cancer risk. Lung Cancer. 88:297–303. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park JJ and Park HA: Prevalence of
cigarette smoking among adult cancer survivors in Korea. Yonsei Med
J. 56:556–562. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen YL, Jeng YM, Chang CN, Lee HJ, Hsu
HC, Lai PL and Yuan RH: TERT promoter mutation in resectable
hepatocellular carcinomas: A strong association with hepatitis C
infection and absence of hepatitis B infection. Int J Surg.
12:659–665. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chiba K, Johnson JZ, Vogan JM, Wagner T,
Boyle JM and Hockemeyer D: Cancer-associated TERT promoter
mutations abrogate telomerase silencing. Elife. 4:Jul 21–2015.doi:
10.7554/eLife.07918. View Article : Google Scholar
|
